Bioventus Inc.
BVSHealthcareNASDAQMedical Devices · Last scanned Jul 16, 2026
Scan Results
Daily timeframeBioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The $810.9M market capitalization puts BVS squarely in small-cap range for its industry. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Market Cap
$810.9M
Beta
0.65
P/E (TTM)
28.50
P/E (Fwd)
13.18
EPS (TTM)
$0.42
EPS (Fwd)
$0.91
ROE
16.5%
ROA
5.6%
Cash
$35.8M
Total Debt
$288.4M
Free CF
$63.3M
52W Change
80.3%
Annual Financials
Cash vs Debt
The company holds $35.8M in cash, though total debt stands at $288.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $63.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 16.5% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $512.1M to $568.1M.
BVS's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Bioventus Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. No single metric tells the full story. Reviewing BVS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.